In his recent Real Money column "And Why Not Own Disruptive Stocks Run by Brilliant People?" Jim Cramer asks the rhetorical question: What do money managers get wrong when trying to value stocks like Beyond Meat ? Beyond Meat has a following and market opportunities far greater than traditional metrics can calculate, and that's why their stocks continue to soar. Aggressive traders could go long BYND on a small dip to $120 or on strength above $135.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Newell Brands Inc (NASDAQ: NWL) is not high quality and it doesn't have a great balance sheet.Instead of Caesars Entertainment Corporation (NASDAQ: CZR), Cramer would buy Penn National Gaming, Inc (NASDAQ: PENN).Schrodinger Inc (NASDAQ: SDGR) is a very, very smart company and a great spec, said Cramer. He likes the stock.See Also: Canopy Growth Set To Become Cannabis Sector Leader, Says BofACramer said NortonLifeLock Inc (NASDAQ: NLOK) is an undervalued stock and it should be bought. He likes it very much.Canopy Growth Corp (NYSE: CGC) is the most legit of all the cannabis stocks, said Cramer. He added that it has a great management.Cramer is deeply committed to Beyond Meat Inc (NASDAQ: BYND) and its CEO. He thinks the stock is terrific, but it's also a wild trader.Pure Storage Inc (NYSE: PSTG) worked its way back and it is pretty good, said Cramer.See more from Benzinga * Fast Money Traders Share Their Thoughts On Beyond Meat * Cramer Comments On IHS Markit Ltd, Pinterest And More * Cramer Shares His Thoughts On MGM Resorts, Starbucks And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
By merging Keurig Green Mountain's coffee prowess with Dr Pepper Snapple's portfolio, I believe the combined business is greater than the sum of its parts. While often seen as the third-place runt in the two-way battle between Coca-Cola and PepsiCo, Keurig Dr Pepper has a nonalcoholic beverage offering for every consumer. Upon merging, Keurig Dr Pepper's big promise to shareholders was earnings growth.
In addition to gaining consumer support, Beyond Meat has an opportunity for strong restaurant relationships, says an analyst at BTIG.
The COVID-19 pandemic has been kind to Beyond Meat and Impossible Foods, two companies that produce plant-based substitutes for hamburger, poultry and now pork (Impossible Foods recently introduced its pork substitute product). Supermarkets are expanding the shelf space given to meat substitutes as a response to coronavirus-related supply-chain disruptions at meat processing plants. No one knows whether the surge in interest and demand for plant-based meat substitute products will be sustained beyond the COVID-19 crisis.
We're starting to see a little light at the end of the coronavirus tunnel. State economies are slowly reopening and the market has recovered mightily from March's historic losses.It's true that as we go forward, the lingering effects of stay-at-home orders, a spiking unemployment rate and desperate stimulus measures make for record uncertainty. But we are also starting to understand which types of stocks ought to benefit when the crisis is resolved. * 7 Excellent Penny Stocks Ready to Roar Here are 7 of the top-rated stocks to buy for a post-crisis rally:InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Co-Diagnostics (NASDAQ:CODX) (A) * Humana (NYSE:HUM) (A) * iBio (NYSE:IBIO) (A) * Moderna (NASDAQ:MRNA) (A) * Alibaba (NYSE:BABA) (B) * Square (NYSE:SQ) (B)Four of these stocks hold "A" ratings on my Portfolio Grader, while two hold "B" ratings. All make smart buys here. Co-Diagnostics (CODX)Source: Shutterstock If you're looking for a post-crisis bump, no list of stocks to buy would be complete without somehow representing the healthcare sector.Enterprising investors should consider CODX as we transition to a new era. Regardless of one's personal thoughts on how to best handle the days ahead, one thing is certain: testing will be absolutely central to any return to normal.For reasons both scientific and psychological, the widespread demand for Covid-19 testing is one of the only givens in these uncertain times. CODX, a previously little-known diagnostics company, was founded in 2013 with a focus on the sale of reagents needed for coronavirus tests.Although Co-Diagnostics shares fell after the most recent earnings report, the roughly $600 million CODX, which has been increasingly watched by investors, makes test kits that should be an important part of re-opening the U.S. economy in 2020, even if accuracy doesn't hit the 100% level the company has claimed.Rating: (A) Humana (HUM)Health insurer Humana has been absolutely shining in 2020, despite the novel coronavirus wreaking havoc across the economy. Shares are up more than 60% year-to-date, and the Louisville, Kentucky-based health plan giant is coming off a killer first-quarter earnings report.In sharp contrast to rivals like Anthem (NYSE:ANTM), which recently withdrew its full-year 2020 guidance, Humana posted blowout Q1 earnings. The company reported revenue of $18.93 billion against analyst expectations for $18.38 billion. On the earnings per share (EPS) side, HUM stock reported EPS of $5.40 versus the $4.84 consensus expectation.The top- and bottom-line beats were also accompanied by an optimistic outlook for the rest of 2020; Humana guided for EPS between $18.25 and $18.75, for a median of $18.50, above the $18.44 per share consensus expectations. * 7 Excellent Penny Stocks Ready to Roar Rating: (A) iBio (IBIO)Source: Shutterstock If there is a coronavirus vaccine, the small-cap biotech iBio could end up being a major beneficiary. Although certainly more speculative in nature than a stock like Humana, the roughly $100 million IBIO could see shares continue to surge when a vaccine is rolled out. Shares of IBIO have already jumped about 500% in 2020, but there's still upside to be had.That's because the company is boasting capacity of about 500 million doses should their much-anticipated vaccine come to fruition. Few investors take the time to think through not just the companies that are researching the vaccine itself, but those that will be necessary to manufacture and distribute the vaccine.The New York, New York-based IBIO has a Texas manufacturing facility that should be able to make 500 million doses of a vaccine annually -- the sort of capacity necessary when a vaccine is invented. In theory, this should be enough capacity to supply and vaccinate not just all of the U.S. (328 million people), but also the entire populations of Mexico (126 million) and Canada (38 million).Rating: (A) Moderna (MRNA)Source: Shutterstock The source of some major market-moving news in recent days, Cambridge, Massachusetts-based Moderna is a clinical biotechnology company. As its ticker indicates, it uses messenger RNA (mRNA) in vaccines and other treatments for infectious diseases.Promising early results in a coronavirus vaccine trial in human patients vaulted MRNA shares to all-time highs and helped send the entire market higher to boot. The phase one trial included 45 participants and saw the production of antibodies in 100% of them, a very encouraging sign as the entire world races to come up with an efficacious vaccine that can be manufactured and distributed at scale. * 7 Excellent Penny Stocks Ready to Roar Rating: (A) Alibaba (BABA)Source: BigTunaOnline / Shutterstock.com Who would've thought that one of the largest companies in China would be listed as one of the best stocks to buy in a post-crisis rally? Although Wuhan, China, was the early epicenter of the global pandemic, China's swift moves to lockdown its sprawling country and rapidly rollout contact tracing mitigated the harm of the pandemic.And BABA stock, for its part, has held up quite well. Like its closest American counterpart Amazon.com (NASDAQ:AMZN), Alibaba has actually leveraged it large market share and impressive logistics network to cement its status as a powerhouse in e-commerce, which has gotten an obvious boost as mandated lockdowns dried up demand across Chinese brick-and-mortar retailers.Trading at 22 times earnings and with a market cap above $500 billion, BABA offers a unique combination of size, growth and affordability. On the growth side, it saw revenue jump 38% last quarter and earnings per share increase 55%.Rating: (B) Square (SQ)Source: Jonathan Weiss / Shutterstock.com Last but not least, payments company Square rounds out our list of the top-rated stocks to buy when the crisis resolves.The provider of point-of-sale solutions for businesses has been a growth stock for some time now, and its solutions include contactless payments -- something that should doubtlessly gain share in the months and years ahead as the pandemic changes consumer behavior.Revenue has grown at a 41% clip over the last five years, and analysts expect profits to be the next metric to really take off in coming years, with consensus expectations calling for a 31% compound annual growth rate in earnings per share over the next five years. * 7 Excellent Penny Stocks Ready to Roar Rating: (B)Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * America's Richest ZIP Code Holds Shocking Secret * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 6 Top-Rated Stocks for a Post-Coronavirus-Crisis Bump appeared first on InvestorPlace.
Plant-based food maker Beyond Meat Inc (NASDAQ: BYND) continues to mostly benefit from the "young female consumer in the urban environment," BTIG analyst Peter Saleh said Thursday on CNBC's "Trading Nation."What HappenedOn Tuesday, Saleh initiated coverage of Beyond Meat's stock on Tuesday with a Buy rating and $173 price target. The bulk of his thesis is based on continued momentum from a strong demographic group where repeat purchase rates are as high as 46% in the grocery store channel.Consumers across coastal cities on both sides of the country are typically trend-starters and the middle of the country is usually "later to adapt," the analyst said. It's a matter of time before Beyond Meat starts to make inroads in the middle of the country.Why It's ImportantBeyond Meat's "really strong demand" makes the case for a greater expansion within the restaurant group, which is in the process of reopening. As it stands today, Beyond Meat's food can be found at 34,000 restaurants in the U.S. which Saleh said implies a penetration rate of just 5%.Beyond Meat's path to expanding market share in the middle of the country would require a compelling marketing initiative, Saleh said. Fortunately, it already benefits from "free marketing by being on all these menu boards" across the country."I think that will help tremendously as they start to grow into the middle of the country," Saleh said.Beyond Meat's stock closed Thursday's session at $138.11 per share.Related Links:These Analysts Aren't Supporting Beyond Meat's Stock SurgeBeyond Meat Brings Jim Cramer One Step Closer To Becoming VeganLatest Ratings for BYND DateFirmActionFromTo May 2020BTIGInitiates Coverage OnBuy May 2020JP MorganMaintainsNeutral May 2020DA DavidsonMaintainsNeutral View More Analyst Ratings for BYND View the Latest Analyst RatingsSee more from Benzinga * Beyond Meat Brings Jim Cramer One Step Closer To Becoming Vegan * These Analysts Aren't Supporting Beyond Meat's Stock Surge * Wells Fargo Says Beyond Meat Is Overcooked, Downgrades Stock(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Many Americans, stuck at home because of the coronavirus pandemic, are putting federal stimulus checks and other money into online stock trading. Several leading brokerage firms have reported a surge in new accounts since much of the U.S. went into lockdown in March, and the stock market’s sharp recovery since the March lows, coupled with recent steps to reopen the U.S. economy, only fuels these newcomers’ euphoria. Indeed, with zero-commissions, day trading seems like an easy way to make a quick buck.
Buying shares of Beyond Meat (NASDAQ: BYND) or McDonald's (NYSE: MCD) is a way to invest in an American classic: the burger. McDonald's reached a peak in annual revenue in 2014, then saw sales slip amid competition from popular fast-casual chains like Chipotle Mexican Grill and competitors with more of an upscale burger like Five Guys.
As we've seen recently, the Dow Jones Industrial Average (DJINDICES: ^DJI) had larger gains than the broader market, but the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) also managed to pick up ground. Among individual stocks, Tesla (NASDAQ: TSLA) shares were surprisingly little changed, even after the electric automaker announced a move that made some fear that vehicle demand could be weaker than previously believed. Tesla shares were up a fraction of a percent Wednesday following news overnight that the automaker had chosen to cut prices of some its vehicles.
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?
Food is a necessity, and with the global population growing by more than 200,000 every day, there are more mouths to feed than ever. This suggests the food industry will continue its growth trajectory over the long term. In the near term, the coronavirus pandemic has created unique challenges and opportunities for many companies in this crucial sector, and that's something investors in the food sector need keep an eye on.
In the spirit of harmony and coming together during these divided times, the New York Times gives us an opinion piece we can all agree on: “The end of meat is here.” Just kidding.
Wall Street is coalescing around the bullish thesis for Beyond Meat (NASDAQ: BYND) as yet another analyst has initiated coverage with a buy rating on the producer of meat alternatives. Thefly.com says BTIG analyst Peter Saleh's investor note says there's a case to be made for supporting companies that "make a difference," and with increased consumer acceptance of plant-based meats, along with future restaurant partnerships, Beyond Meat can be a $173 stock. Shares of Beyond Meat have surged 170% since the spread of COVID-19 was declared a pandemic in mid-March, but Wall Street sees the faux-meat maker having much more upside potential.
Broker BTIG initiated coverage of Beyond Meat shares on Tuesday with a Buy rating and a Street-high $173 price target.
It was a choppy week in the stock market, before investors headed home for a long three-day weekend. Let's use that extra day to look at some top stock trades for next week. Top Stock Trades for Tomorrow No. 1: Alibaba (BABA) Click to EnlargeSource: Chart courtesy of StockCharts.comAlibaba (NYSE:BABA) stock is falling about 6% despite reporting strong earnings and revenue results. Despite the stumble, the charts still look constructive.BABA stock ran into a roadblock around $220, but held the backside of prior downtrend resistance (blue line) ahead of the print. After Friday's fall though, shares lost this level, as well the 20-day moving average.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNow down near $200, shares are coming up into the 50-day moving average. Aggressive bulls may consider buying this dip, giving the quality of the earnings. However, conservative buyers may consider waiting. * 7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine That's as potentially stronger support near $194 comes into play with the 200-day moving average. On a rebound, I want to see shares reclaim downtrend resistance. Top Stock Trades for Tomorrow No. 2: Beyond Meat (BYND) Click to EnlargeSource: Chart courtesy of StockCharts.comBeyond Meat (NASDAQ:BYND) had a relatively quiet week. The stock continues to form a narrowing wedge after its big post-earnings rally.That has bulls optimistic that a break higher may come into play, while bears are hoping the stock runs out of momentum. On the downside, keep an eye on $130. Below this level and below last week's low at $127.21 could spell trouble for the bulls.On the upside, a move over last week's high at $147.55 puts a potential rally to $160 in play. I do like this trade on a break of either level, but prefer the long side for two reasons.First, earnings are out of the way and the reaction was bullish. Second, there are fewer hurdles in the way on a breakout as opposed to a breakdown, with the 20-day moving average coming into play at $122.40. Top Stock Trades for Tomorrow No. 3: Canopy Growth (CGC) Click to EnlargeSource: Chart courtesy of StockCharts.comCanopy Growth (NYSE:CGC) made some great moves today -- and even gave traders an excellent day-trading situation.Friday's rally is interesting. On the one hand, CGC's move is impressive and the stock is rotating over last month's high. I love that. But at the same time, it's coming into the 200-day moving average near $20 and the 200-week moving average near $21.80.That's not a great scenario, although a rally over these market could put the mid-$20s in play. Keep these levels in mind on the upside. On the downside, watch $18.25. That was the April high, and a dip to this level that holds as support could be a buying opportunity. Top Trades for Tomorrow No. 4: Cronos Group (CRON) Click to EnlargeSource: Chart courtesy of StockCharts.comSticking with the cannabis industry, Cronos Group (NASDAQ:CRON) is moving nicely too. Shares are also rotating over last month's high, but could have a bit more room to run.Watch the $6.70 area for possible support on a pullback. On the upside, look for a gap-fill up toward $7.15, with the 200-day moving average and the $8 mark acting as more significant upside marks.This group can move intensely in both directions. But using levels can help pinpoint when the move is real vs. a fake-out. Have a happy Memorial Day weekend.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * America's Richest ZIP Code Holds Shocking Secret * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 4 Top Stock Trades for Tuesday: BABA, BYND, CGC, CRON appeared first on InvestorPlace.
Beyond Meat (NASDAQ:BYND) has fallen out of favor a few times over the last year. But after its most recent earnings report, BYND stock is back on investors' radar. Shares pushed through big-time resistance, and are set up for a possible breakout higher.Source: Shutterstock On May 5th, Beyond Meat reported earnings of 3 cents per share, surprising analysts with a 3-cent beat and a surprise profit. Moreover, revenue grew 141.4% year-over-year to $97.1 million and beat estimates by about $10 million.It was the quarter that bulls needed to see. All those pictures circulating online of fully stocked alternative-meat products no one seemed to want during the pandemic were put to rest -- at least for now. Shares ripped higher by 26% on the report, and are now higher by more than 37%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo, with all of that in mind, let's look at the charts before diving in. Trading BYND Stock Click to EnlargeBYND stock did not end 2019 on a good note, as Q4 was a rough ride. The first day of October was the stock's high for the quarter. Shares hit a high near $150, but ended the month just above $80 and continued to grind along $75 through year-end. * 7 Excellent Penny Stocks Ready to Roar However, once 2020 came around, shares erupted higher -- running from $75 to $130 in less than two weeks. This $130 area became resistance, though, stymying each rally in BYND stock until shares finally rolled over in February with the rest of the market.Fast-forward to May, and the stock was finally able to breakout over this mark on earnings and are now finding $130 as support. Coiling in the mid-$130s now, I think a move to $160-plus is possible. That is, assuming the overall market can hold up as well. If the market rolls over, it's possible that BYND stock will too.Short of that, though, this has all of the makings of a solid breakout. Earnings were strong and are in the rear-view mirror. Shares are through resistance and now holding that level as support. A move above $147.55 -- the May high -- puts $160 in play, followed by the 138.2% extension of the 2020 range, up near $168.Should the breakout fail, however, it puts the 200-day moving average in play. This level was resistance in April and was notably reclaimed on the post-earnings open in BYND stock. Breaking Down Beyond MeatWhen I look at a company's fundamentals, I immediately scope out four areas of interest. These readings give me a quick idea of whether the business is growing and what its financial health is like. Obviously, an exam goes deeper than just the surface, but this gives us a quick idea of what we're dealing with.The list includes: revenue, margins (both gross and operating), free cash flow and assets vs. liabilities.Broken down simply, revenue tells us whether the company is growing or not. That's pretty self-explanatory. Margins can be trickier, though, because contracting margins doesn't necessarily reflect an unhealthy company. But when they are expanding, it's a much-sought after catalyst.We like to see positive free cash flow, but again, there can be some grey area. Finally, weighing assets vs. liabilities helps us determine what type of balance sheet strength is presentIn weak companies -- like Chesapeake Energy (NYSE:CHK) or J.C. Penney (NYSE:JCP) -- we'll see most of these points paint a bleak outlook. In strong companies we'll see the opposite. So for BYND stock, the company does pretty good.Revenue continues to grow at a very healthy clip, going from $32.6 million in 2017 to $87.9 million in 2018 to $297.9 million last year. This year Beyond Meat is forecast to do more than $450 million in sales. Gross and operating margins have been expanding, too.Unfortunately, free cash flow is contracting rather than expanding. That's not the end of the world, although it's not ideal. However, the balance sheet is solid. Cash and short-term securities of $246.4 million crush current liabilities of $71.9 million, while total assets of $491.6 million outweigh total liabilities of $99.6 million.BYND stock is a bit expensive, but it's swinging from a loss to a profit with expanding margins and robust revenue growth.In any regard, though, the technicals look great. And over $130, Beyond Meat stock can continue to rise.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, he held no position in any aforementioned securities. More From InvestorPlace * Top Stock Picker Reveals His Next 1,000% Winner * America's Richest ZIP Code Holds Shocking Secret * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post A Big Breakout Is Brewing in Beyond Meat Stock Right Now appeared first on InvestorPlace.
The plant-based meat substitute maker's CEO talks conquering China, encouraging consumer trials while the global meat supply chain is disrupted, and more.
Portfolio managers are struggling with what to pay for companies if they want to add value and beat the S&P 500. It's hurt by the lack of food service business. It's got reasons, but they are reasons that don't fly with most portfolio managers.
It's been nothing but good news for the fake meat producer this week, but the stock keeps going down regardless.